ABVC BioPharma, Inc. (ABVC): Price and Financial Metrics
ABVC Price/Volume Stats
| Current price | $1.45 | 52-week high | $9.60 |
| Prev. close | $1.59 | 52-week low | $0.67 |
| Day low | $1.40 | Volume | 1,050,713 |
| Day high | $1.57 | Avg. volume | 2,096,610 |
| 50-day MA | $1.21 | Dividend yield | N/A |
| 200-day MA | $1.48 | Market Cap | 15.26M |
ABVC Stock Price Chart Interactive Chart >
ABVC BioPharma, Inc. (ABVC) Company Bio
American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.
Latest ABVC News From Around the Web
Below are the latest news stories about ABVC BIOPHARMA INC that investors may wish to consider to help them evaluate ABVC as an investment opportunity.
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical StudyFREMONT, CA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase II part II clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers. A total of 94 subjects were screened, out of whi |
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical TrialsFREMONT, CA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (“ABVC” or the “Company”) (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today shared an interview with Dr. Scott Irwin, MD, Ph.D., an eminent Professor of Psychiatry and Behavioral Neurosciences at Cedars-Sinai Medical Center (CSMC). Dr. Irwin serves as the Principal Investigator for the clinical trials of ABV-1601, |
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion MarketFREMONT, CA, Nov. 21, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced today that it received a U.S. patent, Application No. 17/120,965, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, which is used in the Company's asset ABV-1505, targeting Attention Deficit/Hyperactivity Disorder ( |
ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200MFREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivit |
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational ResultsFREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023. These results, including the financial statements included herein, can be found in the Company's Quarterly Report on Form 10-Q that was filed earlier today with t |
ABVC Price Returns
| 1-mo | 20.83% |
| 3-mo | 11.54% |
| 6-mo | 5.07% |
| 1-year | -79.29% |
| 3-year | -96.81% |
| 5-year | N/A |
| YTD | 25.00% |
| 2023 | -81.44% |
| 2022 | -81.56% |
| 2021 | -33.53% |
| 2020 | 16.70% |
| 2019 | -87.86% |
Loading social stream, please wait...